Article ; Online: Preclinical and translational pharmacology of afucosylated anti-CCR8 antibody for depletion of tumour-infiltrating regulatory T cells.
British journal of pharmacology
2024
Abstract: Background and purpose: RO7502175 is an afucosylated antibody designed to eliminate C-C motif chemokine receptor 8 (CCR8): Experimental approach: We report findings from preclinical studies characterizing pharmacology, pharmacokinetics (PK)/ ... ...
Abstract | Background and purpose: RO7502175 is an afucosylated antibody designed to eliminate C-C motif chemokine receptor 8 (CCR8) Experimental approach: We report findings from preclinical studies characterizing pharmacology, pharmacokinetics (PK)/pharmacodynamics (PD) and safety profile of RO7502175 and discuss the translational PK/PD approach used to inform first-in-human (FiH) dosing strategy and clinical development in solid tumour indications. Key results: RO7502175 demonstrated selective ADCC against human CCR8 Conclusion and implications: This work demonstrates a translational research strategy for collecting and utilizing relevant nonclinical data, developing a mechanistic PK/PD model and using a comprehensive approach to inform clinical study design for RO7502175. |
---|---|
Language | English |
Publishing date | 2024-03-14 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 80081-8 |
ISSN | 1476-5381 ; 0007-1188 |
ISSN (online) | 1476-5381 |
ISSN | 0007-1188 |
DOI | 10.1111/bph.16326 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Uf I Zs.146: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.